Statins in COPD: A systematic review

Chest

Volumn 136, Issue 3, 2009, Pages 734-743

  Janda, Surinder ^a   Park, Kirly ^a   FitzGerald, J Mark ^a   Etminan, Mahyar ^a   Swiston, John ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COCHRANE LIBRARY; COHORT ANALYSIS; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HUMAN; INFORMATION RETRIEVAL; INTUBATION; LUNG FUNCTION; MEDLINE; METHODOLOGY; OBSERVATIONAL METHOD; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SYSTEMATIC REVIEW;

EID: 69249112121     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-0194     Document Type: Article

References (34)

1. Walsh GM. Defective apoptotic cell clearance in asthma and COPD: a new drug target for statins? Trends Pharmacol Sci 2008; 29:6-11
2. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370:741-750 (Pubitemid 47321907)
3. Murray C. Alternative visions of the future: projecting mortality and disability. In: Murray C, Lopez A, eds. The global burden of disease. Boston, MA: Harvard University Press, 1996; 361-375
4. Thom T. Morbidity and mortality: 2007 chartbook on cardiovascular, lung, and blood diseases. Bethesda, MD: National Institutes of Health, 2007
5. Cosio MG, Guerassimov A. Chronic obstructive pulmonary disease: inflammation of small airways and lung parenchyma. Am J Respir Crit Care Med 1999; 160:S21-S25
6. Saetta M. Airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:S17-S20
7. van Eeden SF, Hogg JC. The response of human bone marrow to chronic cigarette smoking. Eur Respir J 2000; 15:915-921 (Pubitemid 30321851)
8. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59:574-580 (Pubitemid 38901515)
9. Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J 2003; 46(suppl):5s-13s (Pubitemid 37351732)
10. Merx MW, Weber C. Statins in the intensive care unit. Curr Opin Crit Care 2006; 12:309-314
11. Morimoto K, Janssen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol 2006; 176:7657-7665 (Pubitemid 43849066)
12. Walsh G. Statins as emerging treatments for asthma and chronic obstructive pulmonary disease. Expert Rev Resp Med 2008; 2:329-335 (Pubitemid 351959392)
13. Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005; 172:987-993 (Pubitemid 41476535)
14. Takahashi S, Nakamura H, Seki M, et al. Reversal of elastase-induced pulmonary emphysema and promotion of alveolar epithelial cell proliferation by simvastatin in mice. Am J Physiol Lung Cell Mol Physiol 2008; 294:L882-L890
15. Blamoun AI, Batty GN, Debari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008; 62:1373-1378
16. Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131:1006-1012 (Pubitemid 46608700)
17. Ishida W, Kajiwara T, Ishii M, et al. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med 2007; 212:265-273 (Pubitemid 47304993)
18. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007; 132:1764-1771
19. Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008; 101:530-535
20. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47:2554-2560 (Pubitemid 43866389)
21. Melbye H, Halvorsen DS, Hartz I, et al. Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly: the Tromso study 2001. Respir Med 2007; 101:2541-2549
22. Soyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007; 29:279-283 (Pubitemid 46237383)
23. van Gestel YR, Hoeks SE, Sin DD, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008; 102:192-196
24. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting; Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-2012
25. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176:742-747 (Pubitemid 47598474)
26. Falk JA, Kadiev S, Criner GJ, et al. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5:543-548 (Pubitemid 351669184)
27. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28:523-532 (Pubitemid 44794666)
28. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002; 121: 121S-126S
29. US Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: US Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 148:529-534
30. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14:37-44
31. Effect of statins on asthma control in smokers with asthma + pilot study of effect of statins on lung function in COPD. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00463827?term=COPD+and+Statins& rank=1. Accessed July 28, 2009
32. Effect of statin therapy on C-reactive protein levels in patients with chronic obstructive lung disease (COPD). Available at: http://www. clinicaltrials.gov/ct2/show/NCT00655993?term=COPD+and+Statins&rank=2. Accessed July 28, 2009
33. Simvastatin in chronic obstructive pulmonary disease (COPD). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00680641?term= COPD+and+Statins&rank=5. Accessed July 28, 2009
34. Lovastatin as a potential modulator of apoptosis in chronic obstructive pulmonary disease (COPD). Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00700921?term=COPD+and+Statins&rank=4. Accessed July 28, 2009